&nbsp;

Feb 2022

Drug

midostaurin

Other Name(s): Rydapt®

Quick Link(s):

Jun 2025

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

MPT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Exceptional Access Program

thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

IBRU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

IDEL+RITU; IDEL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria

New Drug Funding Program

Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

idelalisib,

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, as monotherapy, based on criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

IBRUVENE

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria

Exceptional Access Program

venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria

Drugs Used:

iBRUtinib,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

IBRU+RITU

Cancer Type:

Hematologic

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2025

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Updated

Sep 2025

Drug

ivosidenib

Other Name(s): Tibsovo®

Quick Link(s):